Skip to main content
Global Site Support
Follow us
✕
Company
Mission
About IXICO
IXI™ Platform
The Power of Neuroimaging
Customers
Partnerships
Leadership Team
Careers
Business Development Director (US)
Associate Clinical Data Manager
Operations Associate
Recruitment privacy notice
IXI™ Platform
Services
Imaging Biomarkers
Radiological reads
Volumetric MRI
PET & SPECT
Advanced MRI
Trial Management
Data Analytics
Post-Marketing Surveillance
Consultancy
Therapeutic Expertise
Alzheimer's Disease (AD)
Huntington's Disease (HD)
Parkinson's Disease (PD)
Multiple Sclerosis (MS)
Other Rare Neurological Diseases
News & Resources
News
Scientific Publications
Webinars
Downloads
Blog
Video
Investors
Share Price
Governance
AIM Rule 26
Our Board
Oversight
Contacts & Advisers
Investor Resources
Company Documents
Financial Calendar
RNS News
Regulatory Email Alert
Shareholder Info
Investor Presentations
Investor Videos
Contact us
Contact Us
Global Site Support
Submit RFP
\
Sitemap
Sitemap
Home
Company
Mission
About IXICO
IXI™ Platform
The Power of Neuroimaging
Customers
Partnerships
Leadership Team
Careers
Business Development Director (US)
Associate Clinical Data Manager
Operations Associate
Recruitment privacy notice
IXI™ Platform
Services
Imaging Biomarkers
Radiological reads
Volumetric MRI
PET & SPECT
Advanced MRI
Trial Management
Data Analytics
Post-Marketing Surveillance
Consultancy
Therapeutic Expertise
Alzheimer's Disease (AD)
Huntington's Disease (HD)
Parkinson's Disease (PD)
Multiple Sclerosis (MS)
Other Rare Neurological Diseases
Recent Scientific Publications
News & Resources
News
Global clinical trial contract wins in Alzheimer’s Disease and Friedreich’s Ataxia
IXICO and Global Alzheimer’s Platform Foundation Announces Strategic Collaboration
Revenues anticipated to be ahead of expectations for the year ending 30 September 2025
IXICO assists first FDA clearance of new Alzheimer’s Disease blood based diagnostic biomarker
Interim results for six months ending 31 March 2025
Half-year Trading update - FY2025
Contract Wins in Alzheimer’s and Huntington’s Disease
Huntington’s Disease consortium further validates IXICO’s AI imaging platform
Commercial agreement with PETNET Solutions Inc, a Siemens Healthineers Company
US Client Clinical Trial Contract Win
Appointment of CEO - Bram Goorden
IXICO to support on Global Alzheimer's Platform Foundation's Bio-Hermes 2 trial
Life Molecular Imaging Collaboration Agreement
Imeka Collaboration Agreement
The impact of diversity on Alzheimer's disease clinical trial design
Huntington’s Disease Image Harmonization Consortium
Call to Action – New consortium will use AI
Engagement in New Consortium
IXICO hails the introduction of IXIQ.Ai, its new brain imaging technology
IXICO primed to solve the challenge of increased clinical trial complexity
Giulio Cerroni in S&P Global Market Intelligence interview
AMYPAD's interview with Katherine Gray
BGF investment fund's Paul Stevens
Investors chronicle: 'IXICO upgrades guidance again'
Investors chronicle: 'Profit from artificial intelligence in neuroscience'
IXICO wins "CRO Provider of the Year 2025" at the Precision Medicine Awards
New blood based biomarker contract win and contract extension worth a total of £1.2 million
Trading update for the year ended 30 September 2025
Capital Markets Day 2025
Global Phase 3 Clinical Trial Contract Win
IXICO strengthens Scientific Advisory Board with two prominent global Alzheimer’s Disease experts
Scientific Publications
Neuroimaging Biomarkers for Friedreich's Ataxia: A Cross-Sectional Analysis of the TRACK-FA Study
Comparison of two natural history studies as part of the HD-IH consortium
Fully automatic detection and quantification of new white matter lesions using deep learning
Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease
Volumetric change across the different Stages of the Huntington’s disease
Erosion of The Supratentorial White Matter Reference
Association between regional volume change and clinical change
A Deep Learning Framework For Clinical Trial Enrichment in Alzheimer’s Disease
Comparison of amyloid positivity and global cortical SUVR
A convolutional neural network-based framework
Automated VMAT2 [18F] AV-133 PET analysis in Parkinson's disease
Fully automatic deep-learning based segmentation of hippocampal subfields
MR Imaging in Ataxias Consensus Recommendation
Validation of IXIQ.Ai+gBSI
Validation of a Jacobian AI-based method
Deep-learning methods for enrichment of Alzheimer’s Disease clinical trials using MRI and PET
Amyloid PET centiloid: impact of calibration and processing steps
Application of fully automatic Hippocampal sub-field segmentation volumes
MDS 2022 Poster
EHDN Imaging Working Group Presentation on new HD-IH Consortium
AD/PD 2021 Poster - Automatic segmentation using deep learning for the hippocampus
AD/PD 2021 Poster
AD/PD 2021 Poster - Added value of wearable sensors for fall risk assessment in an older adult group
IEEE International Conference on Healthcare Informatics (ICHI) 2020 Poster
Huntington Study Group (HSG) 2020 Poster
Huntington Study Group (HSG) 2020 Poster
Alzheimer's Association International Conference (AAIC) Poster 2020
Alzheimer's Association International Conference (AAIC) Poster 2020
Medical Image Understanding and Analysis (MIUA) Publication 2020
Schizophrenia International Research Society (SIRS) 2020 Poster
Quantitative amyloid PET in Alzheimer’s disease: the AMYPAD prognostic and natural history study
Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Poster 2020
Advances in Alzheimer’s and Parkinson’s Therapies (AAT-ADPD) Poster 2020
CHDI Poster 2020
Human Amyloid Imaging (HAI) Poster 2020
Human Amyloid Imaging (HAI) Poster 2020
Clinical Trials on Alzheimer’s Disease (CTAD) Poster 2019
Clinical Trials on Alzheimer’s Disease (CTAD) Poster 2019
Clinical Trials on Alzheimer’s Disease (CTAD) Poster 2019
Company Annual Report 2019
Huntington Study Group (HSG) Annual Meeting Poster 2019
Spinocerebellar Ataxias (SCA) Global Conference 2019 Poster
Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Poster
AI-Driven Recruitment for AD Clinical Trials A Pilot Analysis on the A4 Study Dataset
Webinars
Parkinson's Disease: Unveiling the Promise of Neuromelanin Sensitive Imaging
Neurological Disorders - Harmonisation of Imaging in Clinical Trials
Advancing Alzheimer's Research
Multiple Sclerosis – Advancing treatment through imaging biomarkers
Parkinson's Disease - The road ahead for imaging biomarkers
Huntington's Disease: The present and future of imaging biomarkers
Gene therapy for the CNS: The roles of neuroimaging
Alzheimer’s disease: emerging neuroimaging techniques in clinical trials
Getting neuroimaging right — How to succeed in neurodegenerative clinical trials
Clinical and Imaging Biomarkers in Parkinsonian Syndromes
A deep-learning based framework for brain-atrophy measurement - AD/PD 2021
Using AI To Advance Imaging Operations & Analysis in Phase III Clinical Trials for Alzheimer’s
MIUA 2020: Transfer Learning for Brain Segmentation: Pre-task Selection and Data Limitations
Free Water Imaging in Alzheimer's Disease
Using AI to optimize Tau PET Imaging for Alzheimer’s Disease Clinical Development
AD: Comorbidities, Novel Targets, and Imaging Through the Neuroradiologist’s Lens
Advancing AD Clinical Trials Through Blood-Based Biomarkers & Amyloid PET Webinar
Downloads
Huntington's Disease: Your Imaging Analysis & Operations Solutions Partner
Your Imaging Analysis & Operations Experts in Alzheimer’s Disease Clinical Research
Executing a Multi-Arm Phase 1 Alzheimer’s Disease Global Clinical Trial with Clinilabs and IXICO
Your Partner in Parkinson's Disease Imaging Analysis and Operations Solutions
Blog
Why partnerships are the promising pathway for Alzheimer’s breakthroughs
The New Research Developments Driving Precision Care in Parkinson’s Disease
Imaging of Neurodegeneration within the NIA-AA Research Framework: The ‘N’ in the AT(N) Scheme
Biomarkers and imaging in Alzheimer’s disease
A Quick Guide to Imaging Analysis & Operations Essentials in Alzheimer’s Disease Clinical Research
Innovation Trends in AD Research
Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis
Discussing research multi-biomarker advances in Alzheimer’s Disease at ADPD 2025
International Women's Day 2025
Alzheimer's Disease: The Role of Cutting-Edge Neuroimaging Techniques
How Data, Imaging & AI Are Transforming MS Clinical Research
CHDI's 17th Annual Therapeutics Conference: The Future of Huntington's Research
GAP-Net Site Optimization Conference 2022: Event Review
IXICO & GAP Foundation: Alzheimer’s & The Bio-Hermes Study
Discover IXIQ.Ai | IXICO's AI-Based Brain Segmentation Platform
Interview with IXICO & GAP Foundation
Advancing Clinical And Imaging Biomarkers In Parkinson’s Disease Research
Overcoming Imaging Challenges To Advance Huntington’s Disease Research
Revolutionizing Analytics: The Role of Deep-Learning AI in CNS Clinical Trials
AAIC 2020 Day 3 Summary
AAIC 2020 Day Two Summary
AAIC 2020 Day One Summary
The rise of digital health in the times of COVID-19
A Quick Guide to Imaging Analysis & Operations Essentials in Parkinson’s Disease Clinical Research
Advancing AD Trials: Integrating Plasma Biomarkers and Imaging for Precision Enrolment
Exploring how GLP-1 Drugs and vascular biomarkers are shaping AD clinical trial design
The Emergence of Neuromelanin-Sensitive Imaging in Parkinson’s Disease Clinical Trials
Video
IXICO CEO Bram Goorden on strong 2025 performance and 2026 priorities
Investors
Share Price
Governance
AIM Rule 26
Our Board
Oversight
Contacts & Advisers
Investor Resources
Company Documents
Financial Calendar
RNS News
Regulatory Email Alert
Shareholder Info
Investor Presentations
Investor Videos
Recent Scientific Publications
Contact us
Contact Us
Global Site Support
Submit RFP
Terms and conditions
Privacy Policy
Website Privacy Policy
Business Partner and Supplier Privacy Notice
Site Management Privacy Policy and Terms of Use
Shareholder Privacy Notice
Cookie Policy
Sitemap
